RxDoctor Payments Data

Scarlett Lu, DO

Family Medicine · Sacramento, CANPI 1548373491

Payments from drug & device makers

$812in general payments, 2019–2025

Across 31 payments — averaging $26.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$134
  • GSK$124
  • Baxter Healthcare$117
  • AstraZeneca$98
  • Exact Sciences$66
  • Lilly USA, LLC$48
  • plus $225 from 9 others

What the payments were for

  • Food & beverage$812100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$812 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$56,164
Medicare patients
133
Services billed
847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$62,969
JardianceEmpagliflozin50$62,450
EliquisApixaban31$47,230
RybelsusSemaglutide22$44,298
JanuviaSitagliptin Phosphate26$29,833
FarxigaDapagliflozin Propanediol20$28,880
XareltoRivaroxaban24$24,163
JanumetSitagliptin Phos/Metformin Hcl14$22,869
Janumet XrSitagliptin Phos/Metformin Hcl23$19,207
MounjaroTirzepatide14$13,949
Breo ElliptaFluticasone/Vilanterol14$8,302
Incruse ElliptaUmeclidinium Bromide22$7,659
Wixela InhubFluticasone Propion/Salmeterol25$7,389
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$4,693
BreynaBudesonide/Formoterol Fumarate20$4,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Levemir$46$109,36197 claims
PfizerEliquis$134$47,23031 claims
AstraZenecaFarxiga$98$28,88020 claims
GSKBreo Ellipta, Incruse Ellipta, Arnuity Ellipta$124$19,91957 claims
Lilly USA, LLCMounjaro$48$13,94914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →